Unwanted complement activation is the root cause of many serious inflammatory diseases, including high medical need and orphan indications. We aim to develop bicyclic peptide drugs that inhibit the action of key complement proteins via 1) screening with unique genetically-encoded display libraries of bicyclic '2CLIPS' peptides, 2) lead optimization and 3) preclinical development, incl. PoC in relevant models. This will deliver a first-in class candidate drug attractive to pharma for inlicensing.
